What is the role of flunarizine in migraine prevention?

Flunarizine in Migraine Prevention

Flunarizine is a proven second-line agent for migraine prophylaxis at 10 mg daily, reserved for patients who have failed or cannot tolerate first-line medications (beta blockers, topiramate, or candesartan). 1

Position in Treatment Algorithm

• First-line options must be tried first: Beta blockers without intrinsic sympathomimetic activity (atenolol, bisoprolol, metoprolol, or propranolol), topiramate, or candesartan 1

• Flunarizine becomes appropriate as second-line therapy when first-line agents fail or are contraindicated 1

• Third-line options (CGRP monoclonal antibodies) are reserved for patients who fail both first- and second-line treatments 1

Evidence for Efficacy

The evidence supporting flunarizine is solid but comes with important caveats:

• Proven efficacy at 10 mg/day for reducing migraine frequency, commonly used in countries where available 1

• A 2019 meta-analysis demonstrated flunarizine reduces headache frequency by 0.4 attacks per 4 weeks compared to placebo, with effectiveness comparable to propranolol 2

• However, a 2023 European Headache Federation critical re-appraisal noted that flunarizine trials predate modern endpoints for migraine prophylaxis evaluation, limiting the quality of available evidence 3

• Comparative trial data shows a 4-fold drop in attack frequency, with no significant difference between flunarizine and propranolol 4

Dosing Strategy

• Standard dose: 10 mg once daily at bedtime to minimize daytime sedation 1, 5

• Lower doses (3 mg daily) may reduce side effects while maintaining efficacy, though evidence is limited 6

• Adequate trial period: 2-3 months before assessing efficacy—do not abandon treatment prematurely 1, 5

• After 6-12 months of successful treatment, consider pausing therapy to determine if preventive treatment can be stopped 1

Critical Safety Considerations

Common Adverse Events:

• Sedation/somnolence (most frequent) 1, 5
• Weight gain (reported in up to 32% in some trials) 1, 5, 4
• Abdominal pain 1, 5

Serious Concerns Requiring Caution:

• Depression—particularly in elderly patients: This is a major contraindication 1, 5
• Extrapyramidal symptoms—more common in elderly persons: Avoid flunarizine in this population 1, 5

Patient Selection Algorithm

Use flunarizine when:

1. Patient has ≥2 migraine days per month with disability despite optimized acute treatment 1, 5
2. First-line agents (beta blockers, topiramate, candesartan) have failed or are contraindicated 1
3. Patient has no history of depression 1, 5
4. Patient is not elderly (due to increased risk of depression and extrapyramidal symptoms) 1, 5
5. Patient can tolerate potential weight gain and sedation 1, 5

Avoid flunarizine when:

• Patient has current or past depression 1, 5
• Patient is elderly 1, 5
• Patient has movement disorders or Parkinson's disease (risk of extrapyramidal symptoms) 1
• Weight gain would be particularly problematic (e.g., metabolic syndrome, diabetes) 1, 5

Practical Implementation

• Initiate at 10 mg at bedtime 1, 5
• Counsel patients about expected 2-3 month delay before benefit 1, 5
• Monitor for sedation, weight gain, mood changes, and movement disorders 1, 5
• Avoid concurrent medications that increase sedation 5
• Reassess efficacy at 2-3 months; if ineffective, switch to alternative second-line agent (amitriptyline or, in men only, valproate) 1

Geographic Availability

Flunarizine is commonly used in countries where it is available, but availability varies by region 1. In areas where flunarizine is not available, alternative second-line agents include amitriptyline or sodium valproate (contraindicated in women of childbearing potential) 1.